IRLAB Therapeutics
31.12.2021 10:51:35 CET | ACCESS Newswire | Press release
GOTHENBURG, SE / ACCESSWIRE / December 31, 2021 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)
IRLAB (Nasdaq Stockholm: IRLAB A). Martin Nicklasson has announced his intention to leave the board in January 2022. The background to this decision is his new role as chairman of the board in another company.
According to IRLAB's articles of association, the board shall consist of at least three (3) and at most (10) members. When Nicklasson leaves the board, it will consist of five (5) members, and will thus continue to fulfill this requirement up to the next annual general meeting in May 2022, when a new board shall be chosen.
"On behalf of the board and shareholders I would like to extend a hearty thank-you to Martin for his valuable input to board activities this past year," says Gunnar Olsson, IRLAB's chairman of the board. "2021 has been a transformative period in IRLAB's development. Our successful license deal with mesdopetam and the regulatory approvals for the start of the Phase IIb study with pirepemat have given us a completely new basis for achieving IRLAB's long-term goals."
For more information
Gunnar Olsson, Chair of the board
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se
About IRLAB
IRLAB is a Swedish research and development company that focuses on discovery and development of novel treatments in Parkinson's disease. The company's most advanced drug candidates, Mesdopetam (IRL790), licensed to Ipsen, and Pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through its proprietary research platform, the Integrative Screening Process (ISP), IRLAB has discovered and developed all its projects within Parkinson's disease and will have an ability to also discover drug candidates for other disorders of the central nervous system (CNS), where large and growing medical needs exist. In addition to the Phase IIb clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phases. IRLAB is listed on Nasdaq Stockholm Main Market. More information is found on www.irlab.se.
Attachments
Board member leaves IRLAB for another assignment
SOURCE: IRLAB Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/680352/Board-Member-Leaves-IRLAB-for-Another-Assignment
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
SMBs Attract Talent with AI Upskilling as Large Firms Cut Jobs and Benefits, Study Finds18.8.2026 12:00:00 CEST | Press release
General Assembly study finds role-specific AI training is the most effective approach for SMBs NEW YORK CITY, NY / ACCESS Newswire / August 18, 2026 / Small-to-medium employers (SMBs) see their human talent as a key area of investment for the AI era and are seeing strong impact from role-specific AI training, according to new research from General Assembly, a global leader in practical AI skills training. Layoff and benefit reductions at larger companies have made it easier for SMBs to recruit and retain top talent, say 81% of human resources (HR) leaders at SMBs, while nearly half (47%) of SMBs have already hired from larger firms in the past year. "Growth-stage companies see AI adoption as a catalyst, not a cost-cutting exercise," said Daniele Grassi, CEO of General Assembly. "They're able to move faster to implement AI and scale it quickly, and they're upskilling their workforces accordingly. As talent sees daily headlines around layoffs and benefit reductions, they're increasingly
LiberNovo Previews Support Week 2026, Putting Better Ergonomic Support Within Reach18.8.2026 10:00:00 CEST | Press release
Support Week starts August 25. We've got your back. HONG KONG, HK / ACCESS Newswire / August 18, 2026 / One size does not fit all. Yet most ergonomic chairs are still built around a standard frame, leaving taller, broader, and heavier users adapting to the chair instead of the chair adapting to them. LiberNovo is addressing that gap with the Maxis Series, the lead range for LiberNovo Support Week 2026, opening August 25 across the European Union and United Kingdom. Built for Bigger Builds Maxis was engineered at full scale, not adapted from a standard chair platform. A 52 cm seat depth provides greater thigh support, while a wider seat cushion gives users more room to shift naturally. Its reinforced frame supports up to 181 kg. Maxis also features a five-stage recline control system from 105° to 160°, supported by a Segmented Support System using progressive springs. This provides controlled, consistent support throughout the recline range, even under heavier loads. Three configuration
IFS Softeon Announces Successful First Go-Live with BF Global Group in Europe13.8.2026 14:00:00 CEST | Press release
First deployment marks a major milestone in strategic multi-site warehouse modernisation initiative. RESTON, VA / ACCESS Newswire / August 13, 2026 / IFS Softeon, the warehouse management system (WMS) provider delivering visibility from the boardroom to the warehouse floor, today announced the successful go-live of its warehouse management system at the first BF Global Group distribution centre, marking a significant milestone in the companies' strategic partnership announced earlier this year. The first deployment supports a leading premium stroller and baby products brand and represents the initial phase of BF Global Group's broader rollout of IFS Softeon Warehouse Management System across facilities throughout Europe in partnership with Lanark. The implementation was completed through a carefully coordinated weekend cutover, with operations transitioning successfully to the new platform. Since go-live, the facility has successfully processed and shipped both B2B and B2C customer ord
U.S. Polo Assn. Takes No. 1 Spot for All Sports Brands and Climbs to No. 22 Overall on License Global's 2026 'Top Global Licensors' Ranking13.8.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / August 13, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), was named the highest-ranking sports brand on License Global's annual Top Global Licensor list for the second consecutive year, surpassing the NFL Players Association, PGA Tour, and Formula 1. Marking another milestone, U.S. Polo Assn. climbs to No. 22 overall on the global licensor list spanning the entertainment, fashion, lifestyle, and sports industries. This achievement reflects the continued expansion of the multi-billion-dollar brand globally as it delivered a record year on all fronts with $2.7B in retail sales in 2025. U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), ranked the No. 1 Sports Licensor on License Global's annual Top Global Licensor list. This achievement reflects the continued expansion of the multi-billion-dollar sport brand globally as it delivered a record year on all fronts
Fermi Announces Second Quarter 2026 Results and Delivers on All Five 90-Day Objectives13.8.2026 13:00:00 CEST | Press release
Company Signed Its First Anchor Customer, Named a CEO, Added a Strategic Alliance and Premier Contractors, Received Three F-Series Turbines and Raised More Than $431 Million of Shareholder-Friendly Capital DALLAS, TX / ACCESS Newswire / August 13, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced full execution of the 90-day plan provided in May. The Company established significant momentum and took a major step toward delivering its large-scale, reliable private power grid for AI and advanced computing. The Company also reported second quarter 2026 financial results. A conference call is scheduled for 9 a.m. Eastern Time / 2 p.m. British Time today, August 13, 2026. Accompanying slides and prepared remarks can be found at https://investor.fermiamerica.com. Participation details are included in this release. Delivering on Commitments "Roughly 90 days ago, we put ourselves on the clock with a clear set of aggressive object
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom